Migraine, a debilitating neurological disorder affecting over 1 billion people worldwide, has long challenged medical science due to its complex pathophysiology and variable treatment responses. Single-pulse transcranial magnetic stimulation (sTMS), a noninvasive central neuromodulation technique, has emerged as a promising therapeutic option. Developed by eNeura Inc., the SAVI Dual device leverages sTMS to provide both acute and preventive migraine relief by targeting hyperactive neural networks in the brain. This article explores the technical underpinnings of SAVI Dual, traces the history of clinical studies that shaped sTMS for neuromodulation, and evaluates its position within the evolving migraine market.